Related Experiment Video
Updated: Apr 14, 2026
05:44
Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
Published on: May 24, 2024
1.2K
[Hormone replacement therapy and venous thromboembolism].
Lijecnicki Vjesnik
|April 25, 2015
Summary
Hormone replacement therapy (HRT) increases venous thromboembolism (VTE) risk, especially oral estrogen. Transdermal estrogen and specific progestogens like micronized progesterone may offer a safer alternative for VTE risk reduction.
Area of Science:
- Reproductive Endocrinology
- Thrombosis Research
- Pharmacology
Background:
- Venous thromboembolism (VTE) is a significant risk associated with hormone replacement therapy (HRT).
- Oral estrogen administration is linked to a higher VTE risk compared to transdermal routes.
- The addition of progestogens to estrogen therapy can further elevate VTE risk.
Purpose of the Study:
- To review the association between different hormone replacement therapy (HRT) formulations and venous thromboembolism (VTE) risk.
- To compare the VTE risk profiles of oral versus transdermal estrogen administration.
- To evaluate the impact of various progestogens on VTE risk in HRT users.
Main Methods:
- Review of biological and epidemiological studies on HRT and VTE.
- Analysis of observational data comparing different routes of estrogen administration (oral vs. transdermal).
- Assessment of studies investigating the influence of different progestogen classes on VTE risk.
Main Results:
- Oral estrogen significantly increases VTE risk compared to transdermal estrogen.
- Progestogen addition to estrogen therapy further elevates VTE risk.
- Micronized progesterone and dydrogesterone appear to be associated with lower VTE risk compared to other progestins.
Conclusions:
- Transdermal estrogen is a safer alternative for HRT, particularly for individuals with VTE risk factors.
- Specific progestogens (micronized progesterone, dydrogesterone) may mitigate VTE risk compared to other progestins.
- Randomized controlled trials are needed to confirm the safety of specific progestogens regarding VTE risk.
More Related Videos
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
01:30Venous Thrombosis I: Introduction
724
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
724
01:30Venous Thrombosis IV: Nursing Management
397
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
397
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
445
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
445
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:27Pulmonary Embolism III: Nursing Management
701
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
701